MENSTRUAL CRAMPS TREATMENT MARKET ANALYSIS

Menstrual Cramps Treatment Market, By Drug Class (Analgesics, Anticholinergics, Non-steroidal anti-inflammatory drugs, Haematinics, and Others (Progestins, Among others)), By Type (Primary Dysmenorrhea and Secondary Dysmenorrhea), By Route of Administration (Oral, Injectable, Topical, Intrauterine, and Others (Intrauterine, Among others)), By Dosage Form (Tablet, Capsules, Suspension, and Others (Transdermal Patch, Among others)), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), and By Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa)

Published In : May 2023
Code : CMI5760
Pages :205
Formats :
Excel and PDF
Industry : Pharmaceutical

Menstrual Cramps Treatment MarketSize and Trends

Global menstrual cramps treatment market is estimated to be valued at US$ 652.3 million in 2023 and is expected to exhibit a CAGR of 4.4% during the forecast period (2023-2030).

Global Menstrual Cramps Treatment Market - Drivers

Increasing Product Approvals for Menstrual Cramps Treatment Market

Increasing product approvals for menstrual cramps treatment by regulatory bodies is expected to drive the market growth over the forecast period. For instance, on May 26, 2021, Pfizer Inc., received the U.S. Food and Drug Administration approval for MYFEMBREE. MYFEMBREE (relugolix 40 mg, estradiol 1 mg, and norethindrone acetate 0.5 mg) is once-daily treatment for heavy menstrual bleeding associated with painful periods. It is approved for treatment of Menstrual cramps and duration is up to 24 months. MYFEMBREE Support Program provides services such as insurance benefits checks, co-pay support for commercially insured patients, and patient assistance for qualified uninsured patients.

Global Menstrual Cramps Treatment Market: Key Developments